Essential Medicines Initiative
Advancing essential medicines for critical care scenarios where current options are limited, compromised, or don't yet exist.
Enabled by CellCo's glycan engineering platform and CellFlow — our approach to scalable, precise, novel glycan chemistry.
Glycan Engineering| CellFlow
Structurally defined glycans with enzymatic precision at synthetic speed.
Our Focus in Essential Medicines
Acute Care
Hospital & critical care settings
- Inpatient prophylaxis & treatment
- ICU, surgical, & emergency care
- Interventional & procedural support
Outpatient
Community & chronic care
- Post-discharge continuation therapy
- Chronic & episodic treatment
- Home-administered regimens
Preparedness
Strategic stockpile & field deployment
- Strategic national stockpile
- Forward & field deployment
- Mass casualty surgical triage
Acute Care
Hospital & critical care settings
- Inpatient prophylaxis & treatment
- ICU, surgical, & emergency care
- Interventional & procedural support
Outpatient
Community & chronic care
- Post-discharge continuation therapy
- Chronic & episodic treatment
- Home-administered regimens
Preparedness
Strategic stockpile & field deployment
- Strategic national stockpile
- Forward & field deployment
- Mass casualty surgical triage
Our Programs
Bioxaparin™
Reimagining the world's most used anticoagulant
The world's most prescribed anticoagulant depends on a fragile, single-source supply chain vulnerable to contamination, geopolitical disruption, and animal disease.
patients treated annually
in the U.S. alone
API production in China
single-source dependency
projected market by 2030
fastest-growing anticoagulant
pigs required per year
global supply chain
A fully synthetic enoxaparin built without porcine source material
Powered by CellOS + CellFlow, our biosynthetic process emulates heparin's natural pathway through four sequential in vitro enzymatic steps — delivering a molecule structurally and functionally equivalent to Lovenox®.
The Insulin Story
% Insulin Volume Split by Type
Source: RethinkX, IMS Health, Washington Post, Novo Nordisk
Discovery & First Use
In the 1920s, insulin was discovered and initially extracted from dogs. Produced using cattle pancreases by Eli Lilly in the 1930s, enabling large-scale production.
Recombinant Production
Genentech pioneered synthetic human insulin using recombinant DNA in E. coli. Approved by the FDA in 1982, this innovation transformed diabetes care globally.
The Parallel
Within a decade, recombinant insulin became standard of care — despite costing up to 3x more. Bioxaparin follows the same trajectory: a biosynthetic replacement offering superior consistency, safety, and supply security.
Tissue Repair & Regeneration
Heparin-Mimetic for prevention of acute organ/tissue damage
Acute organ damage destroys the endothelial and epithelial barriers that protect every organ.
Once compromised, fluid leaks, inflammation cascades, and tissue dies. From ARDS to sepsis to radiation injury — there are no approved therapies that directly restore these barriers.
A non-anticoagulant heparan sulfate mimetic engineered to restore barrier function across organs.
Stabilizes growth factors (FGF, VEGF)—accelerates repair
Preserves glycocalyx barrier—protects epithelium and endothelium
Neutralizes DAMPs & histones—dampens inflammation
Inhibits heparanase—prevents ECM breakdown & fibrosis
Acute Respiratory Distress Syndrome
ARDS destroys the alveolar-capillary barrier, causing fluid to flood the lungs. BIOX-2 stabilizes the endothelial glycocalyx to restore barrier integrity and protect lung tissue.
VOD/SOS Prophylaxis
Veno-occlusive disease damages the hepatic sinusoidal lining after bone marrow conditioning. BIOX-2 protects the liver endothelium during transplant conditioning to prevent barrier breakdown.
Sepsis & Systemic Inflammation
Sepsis degrades the glycocalyx systemically, causing vascular leak and cytokine-driven injury across organs. BIOX-2 neutralizes histones and DAMPs to dampen the inflammatory cascade.
Radiation-Induced GI Damage
GI mucositis after radiation or nuclear exposure destroys the gut lining. BIOX-2 preserves epithelial tight junctions and accelerates mucosal repair of the intestinal barrier.
Acute Respiratory Distress Syndrome
ARDS destroys the alveolar-capillary barrier, causing fluid to flood the lungs. BIOX-2 stabilizes the endothelial glycocalyx to restore barrier integrity and protect lung tissue.
VOD/SOS Prophylaxis
Veno-occlusive disease damages the hepatic sinusoidal lining after bone marrow conditioning. BIOX-2 protects the liver endothelium during transplant conditioning to prevent barrier breakdown.
Sepsis & Systemic Inflammation
Sepsis degrades the glycocalyx systemically, causing vascular leak and cytokine-driven injury across organs. BIOX-2 neutralizes histones and DAMPs to dampen the inflammatory cascade.
Radiation-Induced GI Damage
GI mucositis after radiation or nuclear exposure destroys the gut lining. BIOX-2 preserves epithelial tight junctions and accelerates mucosal repair of the intestinal barrier.
CellFlow Scale-Up
CellFlow Synthesis
U.S. Expansion with Partners
Distributed, scalable manufacturing — from factory floor to forward deployment.
- High-purity, modular scale-up
- Unprecedented biomolecule design space
- Precise control of branching, sulfation, and epimerization
Other Approaches
Limited design space, harsh reagents, expensive
Inconsistent structures, supply risk
Imprecise glycan control, low yields
